Press Release: M3 Global Research Acquires pharma-insight GMBH

20 May 2022

Global Healthcare Market Research Leader Strengthens Capabilities and Panel in Germany with Latest Acquisition

FORT WASHINGTON, PA (May 20, 2022) — M3 Global Research announced today the acquisition of pharma-insight GMBH. pharma-insight delivers a comprehensive portfolio of market research services to the life sciences industry, including access to their dedicated healthcare panel, the addition of which further strengthens M3’s proprietary provider panel, the world’s largest. The acquisition follows the recent acquisition of Australia’s Ekas in December 2021, and evidences M3’s strategy for aggressive global growth.

Founded in 2003 by the Baus family, and headquartered in Hilden, Germany, pharma-insight continues under the stewardship of co-founder Gabi Baus and the team, with Guido Baus supporting the integration of pharma-insight into the M3 family as a consultant. Their extensive healthcare research experience has fostered a culture of excellence in delivery, underpinned by strong social commitments and philanthropy, with their support of Wünsch Dir Was e.V.

“We’re delighted to welcome pharma-insight to the M3 family,” said M3 Global Research’s CEO Anton Richter. “Europe remains a strong area of focus for us, and Germany is an important audience for us and our clients. The pharma-insight team’s wealth of experience and deep knowledge of the healthcare space is a perfect fit with M3’s global proposition. This acquisition represents our commitment to continuous investment in our core markets, and we look forward to being able to leverage a dedicated physical presence in Germany for the benefit of our clients.”

pharma-insight co-founder, Gabi Baus on the acquisition: “We’re excited about the opportunities this acquisition presents for the pharma-insight team and our clients. The support and investment from M3 will help us to realise our ambitions, extend the product portfolio for our clients, and grow our business in 2022 and beyond.”

The acquisition further strengthens M3’s European presence, with pharma-insight’s dedicated German call centre, and coverage in Germany, UK, France, Denmark, Netherlands, Norway, Austria, Italy, Poland, Switzerland, Spain, and Czech Republic, alongside capabilities in US, Canada, Brazil, China, Japan, and South Korea.

About M3 Group

The M3 Group operates in the US, Asia, and Europe with over 6 million physician members globally via its physician websites which include,,,,,, and M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Australia, France, Japan, China, and India. The M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Japan, UK, France, Germany, Spain, USA, Sweden, China, South Korea, and India.

About pharma-insight

pharma-insight works closely with target groups across the life sciences and healthcare industries, offering services complementing a full range of qualitative and quantitative methodologies. Their in-depth market knowledge and consultancy offers new perspectives and approaches for their significant client roster.

For more information on the acquisition, please contact Hannah Brown, Head of Marketing, M3 Global Research
Tel: +44 (0)7989 689594